健康元(600380.SH):重組新型冠狀病毒融合蛋白疫苗獲批臨牀試驗
格隆匯3月23日丨健康元(600380.SH)公佈,近日,公司控股子公司麗珠集團控股子公司珠海市麗珠單抗生物技術有限公司(麗珠單抗,公司直接和間接持有的麗珠單抗的權益為55.68%)研發的“重組新型冠狀病毒融合蛋白疫苗”臨牀試驗申請獲國家藥監局批准(批件號2021L90001、2021L90002、2021L90003)。
重組新型冠狀病毒融合蛋白疫苗(V-01)自2020年7月開始立項研發,是麗珠單抗與中國科學院生物物理研究所合作研發的創新型新冠重組蛋白疫苗,具有自主知識產權,屬於新冠疫苗五條技術路線中的重組蛋白疫苗技術路線。V-01為重組蛋白疫苗,可在2-8℃冷鏈運輸及長期儲存。
截至2021年2月28日,V-01已累計研發投入約為人民幣6696.46萬元。
據LSHTM跟蹤器信息,截止2021年3月22日,全球共有86款新冠疫苗產品處於臨牀試驗階段,其中有13款產品已獲批上市或緊急使用授權。國內獲有條件批准上市共4款,獲得緊急使用批准1款,17款處在臨牀試驗階段(重組蛋白技術路線4款)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.